NIBR

Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality

Retrieved on: 
목요일, 5월 2, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, GV, Harvard University, Cancer, Genetics, Cell, Broad Institute, Survival, GV (company), Drug resistance, Growth, Overload, Oncogene, Patient, Neoplasm, NIBR, Investment, MIT, Pharmaceutical industry

Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.

Key Points: 
  • Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.
  • “Our activation lethality platform offers the potential for new cancer medicines that are effective on their own while also combating the emergence of resistance to classic targeted therapies.
  • Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality.
  • Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways.

ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer

Retrieved on: 
월요일, 9월 18, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Boston Consulting Group, BS, Novartis Institute for Tropical Diseases, Biomedical Research, General Electric, Senior, NIBR, Carroll School of Management, Cancer, MBA, Finance, ImmunoGen, IMGN, Accounting, Novartis, Patient, Analysis, Executive Committee, Harvard Business School, Growth, Boston College, Spacecraft, Executive Committee of the Space Research Council, Therapy, Management, Malaria

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer.
  • "We are excited to have Lauren join our team and believe that her expertise in financial planning and strategy, operations, and investor relations will be invaluable as we evolve as a fully-integrated oncology company," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer.
  • She joins ImmunoGen from C4 Therapeutics, where she served as Chief Financial Officer, Treasurer, and Principal Accounting Officer, developing and leading the Company's financial strategy and operations.
  • Prior to this role, she launched the global health business unit as Chief Financial Officer in Basel, Switzerland, and was responsible for several franchises globally.

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

Retrieved on: 
월요일, 7월 24, 2023
Linda, Business development, Novartis Institute for Tropical Diseases, Drug development, Duchenne muscular dystrophy, Therapy, NIBR, University, Biogen, Exosome, Program management, Research, Biomedical Research, CAR, Philip, Vaccine, Patient, SAN, MUSCULAR, Berkeley, Harvard Business School, Drug discovery, Amherst College, Growth, Neurology, Autoimmunity, Massachusetts Institute of Technology, Pharmaceutical industry, Management, Genetics, Novartis, Biology

"It is a pleasure to welcome Philip to our Board of Directors," said Linda Marbán, Ph.D., Capricor’s chief executive officer.

Key Points: 
  • "It is a pleasure to welcome Philip to our Board of Directors," said Linda Marbán, Ph.D., Capricor’s chief executive officer.
  • "Philip has a strong track record for leading research and development programs, from drug discovery through commercialization.
  • His scientific acumen and ability to strategically drive forward business development for research will be invaluable as we continue efforts to advance our cell and exosome technologies.
  • Philip is a tremendous addition to our board, and we look forward to working with him.”
    Dr. Gotwals added, "I am delighted to join Capricor as a member of the board of directors.

Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology

Retrieved on: 
금요일, 7월 21, 2023
Research, Finance, Genetics, Banking, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Myopathy, PNAS, Central nervous system, Biomedical Research, Novartis Institute for Tropical Diseases, Therapy, Executive director, University, NIBR, Investment, The W. Alton Jones Cell Science Center, Sofia University, Deafness, Infection, CureVac, Nature Genetics, Cancer, Howard Hughes Medical Institute, Boston, Multimedia, RNA, Doctor of Philosophy, CNS, Disorder, Messenger, Harvard Medical School, Human genetics, RTÉ Executive Board, Publication, Partner, Patient, Master of Science, The New England Journal of Medicine, RTW, Spectrum, Cardiomyopathy, Hospital, CVAC, Arrhythmia, Gene, III, Disease, Vaccine, Pharmaceutical industry, Achillea millefolium

Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.

Key Points: 
  • Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.
  • Prior to serving as Chief Scientific Officer of CureVac, Dr. Splawski spent fifteen years at the Novartis Institutes for BioMedical Research (NIBR).
  • Dr. Splawski has a PhD in Human Genetics from the University of Utah and an MSc in Biotechnology from Sofia University.
  • Splawski is recognized as a leading figure in the development of complex human genetic tests, protein biologics, and RNA therapies, and we are excited to welcome him to Yarrow,” said Peter Fong, PhD, Chief Executive Officer of Yarrow Biotechnology and Partner and Chief Development Officer at RTW.

Comanche Biopharma Strengthens Board of Directors with Appointment of Dr. Ann Taylor

Retrieved on: 
화요일, 6월 13, 2023
Harvard Medical School, Obesity, Comanche, Novartis, NIBR, Research, DSM-IV codes, Multimedia, Pfizer, AstraZeneca, Management, Pharmaceutical industry

CONCORD, Mass., June 12, 2023 /PRNewswire/ -- Comanche Biopharma is pleased to announce the appointment of Ann Taylor, M.D.

Key Points: 
  • CONCORD, Mass., June 12, 2023 /PRNewswire/ -- Comanche Biopharma is pleased to announce the appointment of Ann Taylor, M.D.
  • Dr. Taylor brings a wealth of experience and expertise, having held academic positions at Harvard Medical School and key leadership roles at Pfizer, Novartis, and AstraZeneca.
  • "We are honored to welcome Dr. Ann Taylor to our Board of Directors," said Scott Johnson, M.D., CEO of Comanche Biopharma.
  • Expressing her enthusiasm for the appointment, Dr. Taylor stated, "I am excited to contribute to Comanche's mission of addressing the global maternal health crisis as a member of the Board of Directors.

The Foundation for the National Institutes of Health Announces the Appointment of Jay Bradner, M.D. and Jim Weiss to the Board of Directors

Retrieved on: 
월요일, 5월 22, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FNIH, Novartis Institute for Tropical Diseases, Therapy, NIBR, Harvard University, Hackathon, Syracuse, Dana–Farber Cancer Institute, Public, Biomedical Research, Genentech, Bangladesh Technical Education Board, Harvard Medical School, Advancement, JQ1, Real Chemistry, Entrepreneurship, Novartis, Patient, University, Chemistry, Executive Committee, Growth, S-1 Executive Committee, Environment and Communications Committee (Iceland), NIH, Disease, S.I. Newhouse School of Public Communications, Management, Pharmaceutical industry

The Foundation for the National Institutes of Health (FNIH) is proud to announce two new additions to the FNIH Board of Directors, Dr. Jay Bradner and Jim Weiss.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) is proud to announce two new additions to the FNIH Board of Directors, Dr. Jay Bradner and Jim Weiss.
  • “We are extremely honored to welcome Jim and Jay to the FNIH Board,” said Steve Paul, M.D., Board Chairman.
  • “They bring incredible entrepreneurship and a commitment to finding innovative solutions to the world’s most challenging health problems.
  • Mr. Weiss will be co-chair of the Advancement and Communications Committee of the FNIH Board and a member of the Executive Committee.

Digital Endpoint Development for Alzheimer's Disease: The Importance of Patients as Partners, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
수요일, 5월 3, 2023
Cambridge Neuropsychological Test Automated Battery, Drug development, NIBR, Biomedical Research, Tapestry (DHT), Associate, Patient, Digital, Health, Alzheimer's disease, Medical imaging

TORONTO, May 3, 2023 /PRNewswire-PRWeb/ -- Digital health technologies (DHTs) like smartphones and wearable sensors hold great promise to advance drug development and discovery in neurodegenerative diseases, particularly Alzheimer's disease. Through objective, continuous, remote capture of real-world outcomes, DHTs have the capacity to measure the impact of novel treatments on how patients with Alzheimer's disease feel and function in their real-world environments, which, in turn, enables the development of drugs that improve aspects of health that matter most to patients. A digital endpoint derived from DHTs thus gives deeper insight on a patient's health.

Key Points: 
  • In this free webinar, learn about how patient engagement can enhance digital endpoint development in Alzheimer's disease clinical trials.
  • To ensure the development of patient-centric endpoints in Alzheimer's disease drug development, engaging patients as partners throughout the process of digital endpoint development is critical.
  • In this webinar, the featured speakers bring together stakeholders representing the perspectives of pharma, technology developers, and most importantly, patients.
  • Register for this webinar today to understand how patient engagement can enhance digital endpoint development in Alzheimer's disease clinical trials.

Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio

Retrieved on: 
금요일, 4월 28, 2023
Antigen, US Food Sovereignty Alliance, Novartis Institute for Tropical Diseases, RA, Biomedical Research, Drug development, NIBR, Investigational New Drug, Biotechnology, ITK, Food and Drug Administration, Research, BTK, Harvard Medical School, Novartis, Patient, Autoimmune disease, Rheumatoid arthritis, Immune system, Human body, Bacteria, FDA, IND, Virus, Food, Disease, Pharmaceutical industry, Vaccine, IQVIA, Daewoong Pharmaceutical

SEOUL, South Korea and OAKLAND, Calif., April 27, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Jeon Sengho and Lee Chang-jae) announced today that it had signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company, on April 28.

Key Points: 
  • With this agreement, Daewoong Pharmaceutical will grant exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio.
  • In return, Daewoong will receive over $10 million in upfront commitments, and the deal is worth up to $477 million.
  • In addition, Vitalli Bio will be granted an option to license earlier stage dual-target inhibitors in development by Daewoong.
  • Daewoong Pharmaceutical will continue to introduce innovative new drugs that are recognized in the global pharmaceutical market."

Aditum Bio Announces Formation of Vitalli Bio, Focused on Immunological Disorders

Retrieved on: 
금요일, 4월 28, 2023
Medicine, Novartis Institute for Tropical Diseases, Biomedical Research, Drug development, NIBR, ITK, CMC, BTK, Novartis, DSM-IV codes, Coronavirus Scientific Advisory Board, Entrepreneurship, Pharmacology, Vaccine, Daewoong Pharmaceutical

OAKLAND, Calif., April 27, 2023 /PRNewswire/ -- Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Vitalli Bio is being formed in connection with the in-licensing of a highly selective dual inhibitor of Interleukin-2-Inducible T-Cell Kinase (ITK) and Bruton's Tyrosine Kinase (BTK) from Daewoong Pharmaceutical, which is anticipated to close in early May. The compound will be renamed VIT-801 and is anticipated to enter Phase 1 studies in 2023.

Key Points: 
  • In addition to VIT-801, Vitalli Bio will be granted an option to license earlier stage dual-target inhibitors in development by Daewoong.
  • "Aditum Bio's translational medicine approach is unique in the industry, and we are excited to move this exciting compound into the clinic in immunological disorders" said Joe Jimenez, Co-Founder and Managing Director of Aditum Bio.
  • Vitalli Bio is the ninth company launched by Aditum Bio, whose mission is to give large patient populations access to medicines which otherwise may not be developed.
  • To speed these drugs to market, Aditum Bio fosters an incubator model, focusing on the translational phase of drug development.

Ochre Bio Strengthens Leadership Team and Board of Directors with Liver Disease Translational Expertise

Retrieved on: 
목요일, 4월 6, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Yale University, Trinity College, Conditional sentence, Abstract, Gastroenterology, NIBR, Internal medicine, Hepatology, Takeda, Bio, SSB, Financial management, Physiology, Postgraduate diploma, Biomedical Research, RNA, Quality, Doctor of Philosophy, Translation, Harvard Medical School, Trinity College Dublin, Development, Novartis, MD, Patient, BWH, Liver, Chronic liver disease, SVP, GI, Takeda Pharmaceutical Company, Management, Pharmaceutical industry, Nursing, Dietary supplement, Pharmacy, Brigham, Chinwe

Ochre Bio, an innovator in chronic liver disease medicine development, is pleased to announce the appointment of David Coughlan, PhD as VP of Translational Development and Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors.

Key Points: 
  • Ochre Bio, an innovator in chronic liver disease medicine development, is pleased to announce the appointment of David Coughlan, PhD as VP of Translational Development and Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors.
  • Dr. Coughlan will be responsible for translating the findings from Ochre Bio’s discovery platform and human-based translational models into RNA therapies ready for clinical development.
  • “Ochre’s end-to-end RNA therapy development, which includes testing in live human donor livers, is an ambitious and bold approach to tackling chronic disease.
  • I look forward to working with both the SSB and the Board to guide Ochre Bio on their path towards impacting patient lives.